Amman:Director General of the Jordan Food and Drug Administration (JFDA) Rana Obeidat confirmed that Jordan holds a pioneering role in regional pharmaceutical studies, supported by advanced legislative frameworks to boost the sector's competitiveness both regionally and internationally.
According to Jordan News Agency, Obeidat made these remarks during the opening of a training workshop titled "The Pharmaceutical Studies Law and Instructions for Conducting Clinical Trials." This event was organized by the ACDIMA Center for Bioequivalence and Pharmaceutical Studies in collaboration with the JFDA and the Jordanian Association of Pharmaceutical Manufacturers (JAPM). She also stated that the JFDA will soon reveal the main themes of its upcoming international conference, which aims to advance pharmaceutical research. Clinical trials and bioequivalence studies are crucial for innovation, scientific research, and ensuring drug safety, efficacy, and quality, she added.
Hanan Al-Sboul, Secretary-General of JAPM, emphasized Jordan's extensive expertise and skilled workforce in pharmaceutical research. She noted that partnerships between the JFDA, academic centers, research institutes, and drug manufacturers are crucial for fostering national innovation and growth within the sector.
The workshop featured a panel discussion on the regulatory framework for pharmaceutical trials. Rima Atoum, Head of the JFDA Pharmaceutical Studies Department, explained the legal requirements, Good Clinical Practice (GCP) guidelines, and responsibilities of stakeholders, including ethics committees and principal investigators.
Additionally, the Head of the Narcotics and Psychotropic Substances Department provided insights into the regulatory controls over the possession, licensing, storage, and handling of controlled substances in clinical research.
The second session of the workshop focused on strategies for maintaining sector leadership and improving the capabilities of local research centers through strategic recommendations.